|
Join our online community
|
|
Advertisement:
Accelerate Sterile and Non-Sterile Clinical Trial Manufacturing with Single-Use Technologies
Live Webcast: Wednesday, March 6, 2013 at 11:00 AM ET
Register Free at http://www.pharmtech.com/
accelerate |
|
|
 |
 |
 |
Advertisement:
Together: It's how we work. It's how we help Pharma Succeed.
Look to Agilent for real world solutions that help pharmaceutical companies discover more rapidly and more efficiently.
The Agilent RapidFire High-throughput System and 6550 iFunnel Q-TOF mass spec helped one lab reduce a week of work to 4.5 hours, transforming their productivity. Discover more, and request your free ADME Solutions Guide at our new pharma web page: www.agilent.com/chem/togetherADME |

- Amgen has announced plans to build a new manufacturing facility in the Tuas Biomedical Park area of Singapore. Over the next several years, Amgen anticipates investing approximately $200 million to build the facility.
- Accelrys, a provider of scientific innovation lifecycle-management software, has agreed to acquire Vialis, a systems integrator serving the pharmaceutical, biotechnology, chemicals, and agroscience industries.
- Almac has completed its Knowledge Transfer Partnership (KTP) with Queens University Belfast intended to develop, improve, and embed bioprocesses to facilitate the delivery of novel products for its biocatalysis business.
- Daiichi Sankyo and Ranbaxy Laboratories have agreed to integrate their business operations in Thailand, to leverage and maximize the synergies of the hybrid business model, which is expected to commence business on Apr. 1, 2013.
- Read More Industry Briefs.
|
|
|
|
|
|
|
|
What area do you think will see increased regulatory attention and enforcement in 2013? |
|
Foreign APIs |
32% |
|
|
GMP inspections |
19% |
|
|
|
|
Manufacturing processes |
13% |
|
|
|
|
Counterfeit medicines |
28% |
|
|
|
|
Social media and digital marketing |
8% |
This week we would like to know...
Which of the following has had the most significant advances in PAT over the last 5 years?

|
|
|
Contact Us
Click here to contact editorial.
Click here to contact sales. |
|
|